MeSH term | MeSH ID | Detail |
---|---|---|
Gastritis | D005756 | 27 associated lipids |
Anemia, Sickle Cell | D000755 | 34 associated lipids |
Sickle Cell Trait | D012805 | 4 associated lipids |
beta-Thalassemia | D017086 | 5 associated lipids |
2,2-DIMETHYLBUTYRIC ACID is a lipid of Fatty Acyls (FA) class. The involved functions are known as Fermentation, Process, Intestinal Absorption, Energy Metabolism and Proteolysis. 2,2-dimethylbutyric acid often locates in host and Hepatic. The related lipids are Propionate, Butyrates, n-Butyrate, Valerates and blood lipid.
To understand associated biological information of 2,2-DIMETHYLBUTYRIC ACID, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
There are no associated biomedical information in the current reference collection.
We collected disease MeSH terms mapped to the references associated with 2,2-DIMETHYLBUTYRIC ACID
MeSH term | MeSH ID | Detail |
---|---|---|
Gastritis | D005756 | 27 associated lipids |
Anemia, Sickle Cell | D000755 | 34 associated lipids |
Sickle Cell Trait | D012805 | 4 associated lipids |
beta-Thalassemia | D017086 | 5 associated lipids |
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Knapp E et al. | Intrapatient variability in fetal hemoglobin measurements over time in sickle cell patients not on fetal hemoglobin inducing agents. | 2016 | Am. J. Hematol. | pmid:26661045 |
Dai Y et al. | Therapeutic fetal-globin inducers reduce transcriptional repression in hemoglobinopathy erythroid progenitors through distinct mechanisms. | 2016 | Blood Cells Mol. Dis. | pmid:26603726 |
Mehraei M et al. | Target-based drug discovery for [Formula: see text]-globin disorders: drug target prediction using quantitative modeling with hybrid functional Petri nets. | 2016 | J Bioinform Comput Biol | pmid:27431020 |
Patthamalai P et al. | A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia. | 2014 | Blood | pmid:24652964 |
Reid ME et al. | A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. | 2014 | Am. J. Hematol. | pmid:24677033 |
Inati A et al. | A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in β-thalassaemia intermedia. | 2014 | Br. J. Haematol. | pmid:24224649 |
Kutlar A et al. | A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. | 2013 | Am. J. Hematol. | pmid:23828223 |
Fucharoen S et al. | A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia. | 2013 | Br. J. Haematol. | pmid:23530969 |
Kutlar A et al. | A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. | 2012 | Am. J. Hematol. | pmid:22887019 |
Bhatia MS et al. | Synthesis, characterization and quantification of simvastatin metabolites and impurities. | 2011 Jul-Sep | Sci Pharm | pmid:21886906 |